Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 17, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data relates to a share buyback transaction:
- Shares Purchased: 1,550,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,318.5572 pence per share.
- Treasury Holdings: Following the purchase, the Company holds 394,637,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 7.01% of total voting rights.
- Shares in Issue: 5,628,842,105 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 1,550,000 shares on September 17, 2007, authorized by shareholders at the Annual General Meeting on May 23, 2007. These shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,628,842,105) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (394,637,158) and its impact on total voting rights (7.01%).
- Note that this filing is a notification of a specific transaction and does not include periodic financial results.